AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01245621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early palliative care intervention
Description: 1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan.
Study NCT04945122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4mg Qn
Study NCT04945122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20mg Qn
Study NCT03466307 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasonographic examination of shoulder
Study NCT03712774 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ OES-18
Description: standardized questionaire
Study NCT03712774 — intervention group
Intervention type: OTHER
Intervention: EORTC OG-25
Description: standardized questionaire
Study NCT03299478 — intervention group
Intervention type: OTHER
Intervention: Will look for immune infiltration
Study NCT01007175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 10 mg q4wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
Study NCT01007175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 30 mg q4wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
Study NCT01007175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 80 mg q4wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
Study NCT01007175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 10 mg q8wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
Study NCT01007175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 80 mg q8wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
Study NCT02476604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coaching and electronic messaging
Description: Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
Study NCT00704067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported employment plus cognitive training
Description: Supported employment for 12 months plus cognitive training for the first 12 weeks
Study NCT03691259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballet Classes
Description: Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
Study NCT01388738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citicoline
Description: citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os
Study NCT00704067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced supported employment
Description: Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
Study NCT00710398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise - Aerobic and Resistance
Description: Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
Study NCT00710398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary - Caloric Restriction
Description: Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.~Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake.
Study NCT00925002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafamidis
Description: 20 mg oral Fx-1006A daily
Study NCT03757429 — intervention group
Intervention type: OTHER
Intervention: RS-virus infection
Description: The intervention consists of lower respiratory tract infection due to RS-virus
Study NCT03012334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Dose is based on treatment sequence in 5-way crossover
Study NCT03012334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Active comparator based on treatment sequence in 5-way crossover
Study NCT01388738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Alpha glycerylphosphorylcholine
Description: choline alfoscerate IV 1000mg daily 10 days
Study NCT01388738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cerebrolysin
Description: Cerebrolysin IV 10 ml daily 10 days
Study NCT00454896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VESIcare®
Description: Oral
Study NCT00454896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral
Study NCT03965039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dipotassium oxalate toothpaste
Description: Experimental dipotassium oxalate (3%) toothpaste
Study NCT03965039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous fluoride toothpaste
Description: Marketed stannous fluoride (0.454%) toothpaste
Study NCT03206112 — intervention group
Intervention type: OTHER
Intervention: PAS25
Description: We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
Study NCT03206112 — intervention group
Intervention type: OTHER
Intervention: PAS10
Description: We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of
Study NCT03206112 — intervention group
Intervention type: OTHER
Intervention: PAS25-cTBS150
Description: We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
Study NCT01998880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
Study NCT01998880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
Study NCT01998880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Study NCT01998880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Study NCT03358654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells from umbilical cord
Description: inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
Study NCT01149343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2302025A, different formulations
Description: Intramuscular administration
Study NCT02752230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy
Study NCT03941067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-event massage
Description: Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands
Study NCT03012334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator based on treatment sequence in 5-way crossover
Study NCT00325143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Description: 1 intramuscular injection (3rd study vaccine dose)
Study NCT00325143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine
Description: 3 intramuscular injections (1st, 2nd and 4th vaccine dose)
Study NCT04194879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multi-target FIT-DNA analysis
Description: ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
Study NCT01711541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01711541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03674983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Economic Incentive (CEI)
Description: If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes.
Study NCT03645538 — intervention group
Intervention type: OTHER
Intervention: Parkinson's disease patients
Description: The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.
Study NCT03645538 — intervention group
Intervention type: OTHER
Intervention: No drug
Description: The neurophysiological evaluation in healthy subjects will be conducted by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.
Study NCT00497900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily vitamin D (cholecalciferol) tablets and rocaltrol
Study NCT00497900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Daily vitamin D (cholecalciferol) tablets and rocaltrol
Study NCT03965039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate toothpaste
Description: Marketed potassium nitrate (5%) toothpaste
Study NCT03965039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium monofluorophosphate toothpaste
Description: Marketed sodium monofluorophosphate (0.76%) toothpaste
Study NCT01711541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT01711541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Given PO
Study NCT01711541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01711541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01711541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO
Study NCT01711541 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT01711541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT02591888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
Study NCT02591888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
Study NCT01596530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug-AZD8931
Description: Active drug for biological activity
Study NCT01596530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug-Placebo
Description: Placebo comparator for biological activity comparison
Study NCT03385499 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood additional samples
Description: additional samples of mother's blood and umbilical cord at delivery
Study NCT03874351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial direct current stimulation (tDCS)
Description: Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.
Study NCT03874351 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non-invasive transcranial direct current stimulation (tDCS)
Description: Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.
Study NCT03036423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online video education
Study NCT03036423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized mental exercises
Study NCT04238572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction device
Description: Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption
Study NCT04238572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia nociception index
Description: ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
Study NCT04238572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia nociception index
Description: ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
Study NCT02972112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: novel cognitive behavioral protocol for the treatment of tokophobia
Study NCT02972112 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: standard birth preparation sessions.
Study NCT02999100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH Oxytocin
Description: Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
Study NCT02999100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Oxytocin
Description: Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
Study NCT02999100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Oxytocin
Description: Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
Study NCT02999100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTAHALER
Description: ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
Study NCT04925518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop Mechanical Ventilation
Description: Closed loop ventilation mode (Intellivent-ASV+®). Intellivent-ASV+® was initiated by activating the controllers for minute volume, PEEP (range 5 to 18 cmH2O) and fraction of inspired oxygen (FiO2) (range 21 to 100 %). The target shift ranges for CO2-management were set between -2.5 and +2.5 kPa, and for O2-management between -2 and +2 %.
Study NCT04925518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Mechanical Ventilation
Description: Mechanical ventilation with a conventional mode, usually either biphasic positive airway pressure ventilation (DuoPAP®) or adaptive support ventilation (ASV®)
Study NCT03490435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tests for diagnosis of intestinal parasitic diseases
Description: Feces testing:~1. fresh fecal samples will be used to preparing direct (saline and iodine wet) mounts using supplementary techniques (flotation, sedimentation), as well as temporary mounts (hematoxylin and trichrome staining). Other technique of fresh fecal samples examination will be ParaSys™~2. A non-preserved stool samples will be stored below -20°C. Defrosted fecal specimen will be subjected to enzyme-linked immunosorbent assays (ELISA) - Giardia antigen test (coproantigens)
Study NCT03097029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatic Enzyme
Description: All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
Study NCT03059472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1 (Intervention)
Description: The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network.
Study NCT03059472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2 (Delayed intervention)
Description: The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network.